Literature DB >> 36093229

One-pot two-step catalytic synthesis of 6-amino-2-pyridone-3,5-dicarbonitriles enabling anti-cancer bioactivity.

Lynden G Nicely1, Ruturajsinh M Vala2, Dipti B Upadhyay2, Joaquina Nogales1, Celestine Chi3, Sourav Banerjee1, Hitendra M Patel2.   

Abstract

We report a one-pot two-step synthesis of a bioactive 6-amino-2-pyridone-3,5-dicarbonitrile derivative using natural product catalysts betaine and guanidine carbonate. Anti-cancer bioactivity was observed in specific molecules within the library of 16 derivatives. Out of the compounds, 5o had the most potent anti-cancer activity against glioblastoma cells and was selected for further study. Compound 5o showed anti-cancer properties against liver, breast, lung cancers as well as primary patient-derived glioblastoma cell lines. Furthermore, 5o in combination with specific clinically relevant small molecule inhibitors induced enhanced cytotoxicity in glioblastoma cells. Through our current work, we establish a promising 6-amino-2-pyridone-3,5-dicarbonitrile based lead compound with anti-cancer activity either on its own or in combination with specific clinically relevant small molecule kinase and proteasome inhibitors. This journal is © The Royal Society of Chemistry.

Entities:  

Year:  2022        PMID: 36093229      PMCID: PMC9400646          DOI: 10.1039/d2ra03579k

Source DB:  PubMed          Journal:  RSC Adv        ISSN: 2046-2069            Impact factor:   4.036


  16 in total

1.  Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.

Authors:  Patrick Y Wen; Mehdi Touat; Brian M Alexander; Ingo K Mellinghoff; Shakti Ramkissoon; Christine S McCluskey; Kristine Pelton; Sam Haidar; Sankha S Basu; Sarah C Gaffey; Loreal E Brown; Juan Emmanuel Martinez-Ledesma; Shaofang Wu; Jungwoo Kim; Wei Wei; Mi-Ae Park; Jason T Huse; John G Kuhn; Mikael L Rinne; Howard Colman; Nathalie Y R Agar; Antonio M Omuro; Lisa M DeAngelis; Mark R Gilbert; John F de Groot; Timothy F Cloughesy; Andrew S Chi; Thomas M Roberts; Jean J Zhao; Eudocia Q Lee; Lakshmi Nayak; James R Heath; Laura L Horky; Tracy T Batchelor; Rameen Beroukhim; Susan M Chang; Azra H Ligon; Ian F Dunn; Dimpy Koul; Geoffrey S Young; Michael D Prados; David A Reardon; W K Alfred Yung; Keith L Ligon
Journal:  J Clin Oncol       Date:  2019-02-04       Impact factor: 44.544

2.  A Single Kinase Generates the Majority of the Secreted Phosphoproteome.

Authors:  Vincent S Tagliabracci; Sandra E Wiley; Xiao Guo; Lisa N Kinch; Eric Durrant; Jianzhong Wen; Junyu Xiao; Jixin Cui; Kim B Nguyen; James L Engel; Joshua J Coon; Nick Grishin; Lorenzo A Pinna; David J Pagliarini; Jack E Dixon
Journal:  Cell       Date:  2015-06-18       Impact factor: 41.582

3.  Syrbactin-class dual constitutive- and immuno-proteasome inhibitor TIR-199 impedes myeloma-mediated bone degeneration in vivo.

Authors:  Vasudha Tandon; Ruturajsinh M Vala; Albert Chen; Robert L Sah; Hitendra M Patel; Michael C Pirrung; Sourav Banerjee
Journal:  Biosci Rep       Date:  2022-02-25       Impact factor: 3.840

4.  Phase I study of vinblastine in combination with nilotinib in children, adolescents, and young adults with refractory or recurrent low-grade glioma.

Authors:  Stephanie Vairy; Gwénaël Le Teuff; Francisco Bautista; Emilie De Carli; Anne-Isabelle Bertozzi; Anne Pagnier; Fanny Fouyssac; Karsten Nysom; Isabelle Aerts; Pierre Leblond; Frederic Millot; Claire Berger; Sandra Canale; Angelo Paci; Vianney Poinsignon; Aurelie Chevance; Monia Ezzalfani; Dominique Vidaud; Angela Di Giannatale; Raquel Hladun-Alvaro; Francois M Petit; Gilles Vassal; Birgit Geoerger; Marie-Cécile Le Deley; Jacques Grill
Journal:  Neurooncol Adv       Date:  2020-06-09

5.  A simplified green chemistry approaches to synthesis of 2-substituted 1,2,3-triazoles and 4-amino-5-cyanopyrazole derivatives conventional heating versus microwave and ultrasound as ecofriendly energy sources.

Authors:  Khadijah M Al-Zaydi
Journal:  Ultrason Sonochem       Date:  2009-02-27       Impact factor: 7.491

6.  Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor.

Authors:  Huimin Hu; Quanhua Mu; Zhaoshi Bao; Yiyun Chen; Yanwei Liu; Jing Chen; Kuanyu Wang; Zheng Wang; Yoonhee Nam; Biaobin Jiang; Jason K Sa; Hee-Jin Cho; Nam-Gu Her; Chuanbao Zhang; Zheng Zhao; Ying Zhang; Fan Zeng; Fan Wu; Xun Kang; Yuqing Liu; Zenghui Qian; Zhiliang Wang; Ruoyu Huang; Qiangwei Wang; Wei Zhang; Xiaoguang Qiu; Wenbin Li; Do-Hyun Nam; Xiaolong Fan; Jiguang Wang; Tao Jiang
Journal:  Cell       Date:  2018-10-18       Impact factor: 41.582

7.  Synthesis and in vitro study of antiproliferative benzyloxy dihydropyrimidinones.

Authors:  Ruturajsinh M Vala; Mayank G Sharma; Divyang M Patel; Adrián Puerta; José M Padrón; Venkatachalam Ramkumar; Ramesh L Gardas; Hitendra M Patel
Journal:  Arch Pharm (Weinheim)       Date:  2021-02-15       Impact factor: 3.751

8.  A novel substrate directed multicomponent reaction for the syntheses of tetrahydro-spiro[pyrazolo[4,3-f]quinoline]-8,5'-pyrimidines and tetrahydro-pyrazolo[4,3-f]pyrimido[4,5-b]quinolines via selective multiple C-C bond formation under metal-free conditions.

Authors:  Divyang M Patel; Hetal J Patel; José M Padrón; Hitendra M Patel
Journal:  RSC Adv       Date:  2020-05-22       Impact factor: 4.036

9.  Impact of an aryl bulky group on a one-pot reaction of aldehyde with malononitrile and N-substituted 2-cyanoacetamide.

Authors:  Ruturajsinh M Vala; Divyang M Patel; Mayank G Sharma; Hitendra M Patel
Journal:  RSC Adv       Date:  2019-09-13       Impact factor: 4.036

10.  Efficacy of osimertinib against EGFRvIII+ glioblastoma.

Authors:  Gustavo Chagoya; Shawn G Kwatra; Cory W Nanni; Callie M Roberts; Samantha M Phillips; Sarah Nullmeyergh; Samuel P Gilmore; Ivan Spasojevic; David L Corcoran; Christopher C Young; Karla V Ballman; Rohan Ramakrishna; Darren A Cross; James M Markert; Michael Lim; Mark R Gilbert; Glenn J Lesser; Madan M Kwatra
Journal:  Oncotarget       Date:  2020-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.